Loading...
•
Mar 31, 2025
Cytek Biosciences Q1 2025 Earnings Report
Estimated Revenue:$42.4M
-0.7% YoY
Estimated EPS:$0.00996
+120.4% YoY
Key Takeaways
Cytek Biosciences reported a decrease in total revenue for the first quarter of 2025 compared to the same period last year, primarily due to a slowdown in product sales in the US and EMEA. Despite this, the company saw strength in the APAC region and double-digit revenue growth in cell sorters and service businesses. Net loss increased compared to the prior year.
Total revenue for Q1 2025 was $41.5 million, a 7.6% decrease year-over-year.
Gross profit for Q1 2025 was $20.2 million, a 12% decrease year-over-year.
Net loss for Q1 2025 was $11.4 million, compared to a net loss of $6.2 million in Q1 2024.
Cash and marketable securities were $265.6 million as of March 31, 2025.
Revenue by Segment
Forward Guidance
Cytek Biosciences revises its full year 2025 revenue guidance.
Positive Outlook
- Full year 2025 revenue guidance is in the range of $196 million to $210 million.
- Guidance represents growth of -2% to 5% over full year 2024.
- Guidance assumes no change in currency exchange rates.
Challenges Ahead
- Revised guidance includes a potential decrease in revenue compared to the prior year.
- The lower end of the guidance range represents a 2% decline.
- Macroeconomic backdrop is challenging.
- Slowdown in product sales in the US and EMEA impacted Q1 results.
Loading...
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...